http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020095299-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f47c750954e13a1ed0be96c1bf1c51c7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-081 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5038 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0619 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2019-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_015ba7552d47f2b4cea266f0f92f72ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99c253fc9791e175d84a2bd265f3ba06 |
| publicationDate | 2020-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020095299-A1 |
| titleOfInvention | STEM CELL MODEL OF APOE GENOTYPE AND Abeta42-DEPENDENT NEURODEGENERATION AND METHODS OF USING THE SAME |
| abstract | Provided is an isolated cell including a modified amyloid beta precursor protein (APP) gene. The modified APP gene encodes a secretory peptide, and the secretory peptide is Amyloid Beta 1-40 (Aβ 1-40 ) or Amyloid Beta 1-42 (Aβ 1-42 ). The isolated cell can additionally have a modified Apolipoprotein E (APOE) gene, and/or at least one marker. Also provided is an in vitro model including at least one population of cells having a modified APP gene encoding a secretory peptide such as Aβ 1-40 or Aβ 1-42 . The population of cells is subjected to at least one differentiation protocol. Further provided is a method of screening treatments including contacting at least one population of cells disclosed herein with at least one agent and determining if the agent has an effect on phenotype. The agent is a drug, a salt, a mineral, an antibody, a humanized antibody, an enzyme, a protein, a peptide, a cell, a modified cell, a stem cell, a plant-based substance, a plant derivative, an antioxidant, or an antioxidant derivative. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022154343-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114569720-A |
| priorityDate | 2018-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.